113 related articles for article (PubMed ID: 34080646)
21. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.
Choi SH; Tamura K; Khajuria RK; Bhere D; Nesterenko I; Lawler J; Shah K
Mol Ther; 2015 Feb; 23(2):235-43. PubMed ID: 25358253
[TBL] [Abstract][Full Text] [Related]
23. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Tian X; Ye J; Alonso-Basanta M; Hahn SM; Koumenis C; Dorsey JF
J Biol Chem; 2011 Aug; 286(33):29408-29416. PubMed ID: 21697087
[TBL] [Abstract][Full Text] [Related]
24. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
25. Overcoming TRAIL Resistance for Glioblastoma Treatment.
Deng L; Zhai X; Liang P; Cui H
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33919846
[TBL] [Abstract][Full Text] [Related]
26. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
27. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.
Panner A; James CD; Berger MS; Pieper RO
Mol Cell Biol; 2005 Oct; 25(20):8809-23. PubMed ID: 16199861
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
29. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
30. PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism.
Serrano-Saenz S; Palacios C; Delgado-Bellido D; López-Jiménez L; Garcia-Diaz A; Soto-Serrano Y; Casal JI; Bartolomé RA; Fernández-Luna JL; López-Rivas A; Oliver FJ
Cell Death Dis; 2019 Jan; 10(2):51. PubMed ID: 30718520
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of c‑FLIP and upregulation of DR‑5 by cantharidin sensitizes TRAIL‑mediated apoptosis in prostate cancer cells via autophagy flux.
Nazim UM; Yin H; Park SY
Int J Mol Med; 2020 Jul; 46(1):280-288. PubMed ID: 32319535
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
Kawakami K; Joshi BH; Puri RK
Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
Candolfi M; Xiong W; Yagiz K; Liu C; Muhammad AK; Puntel M; Foulad D; Zadmehr A; Ahlzadeh GE; Kroeger KM; Tesarfreund M; Lee S; Debinski W; Sareen D; Svendsen CN; Rodriguez R; Lowenstein PR; Castro MG
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20021-6. PubMed ID: 21030678
[TBL] [Abstract][Full Text] [Related]
34. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Bagci-Onder T; Agarwal A; Flusberg D; Wanningen S; Sorger P; Shah K
Oncogene; 2013 Jun; 32(23):2818-27. PubMed ID: 22824792
[TBL] [Abstract][Full Text] [Related]
35. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
36. Targeting eIF4A using rocaglate CR‑1‑31B sensitizes gallbladder cancer cells to TRAIL‑mediated apoptosis through the translational downregulation of c‑FLIP.
Cao Y; He Y; Yang L; Luan Z
Oncol Rep; 2021 Jan; 45(1):230-238. PubMed ID: 33416145
[TBL] [Abstract][Full Text] [Related]
37. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
[TBL] [Abstract][Full Text] [Related]
38. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
[TBL] [Abstract][Full Text] [Related]
39. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells.
Yoshimura S; Sano E; Hanashima Y; Yamamuro S; Sumi K; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2019 Dec; 42(6):2635-2643. PubMed ID: 31638255
[TBL] [Abstract][Full Text] [Related]
40. DR4-Ser424
Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
